Izotropic Corporation Cancels Stock Options

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



    

Vancouver BC / TheNewswire / January 29, 2019.  Izotropic Corporation (CSE: IZO) is reporting the cancellation of the stock options to the following consultants who are no longer engaged by the Company: Robert Lunde was issued 100,000 Options on October 10, 2018 with an exercise price of $0.40 for one year, and; Peymon Gazi was issued 200,000 Options on September 20, 2017 with an exercise price of $0.10 for a period of five years. These two options are now cancelled.

   

About Izotropic Corp.

The company is engaged in the development and commercialization of next-generation, 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides a true 360-degree-view acquisition and delivers high diagnostic accuracy.

The company has also established a wholly owned U.S subsidiary called Isotropic Imaging Corp in 2016 to advance the company’s breast imaging development.

Phone: 1-833-IZOCORP
Email: [email protected]
Website: www.izocorp.com

      

Copyright (c) 2019 TheNewswire - All rights reserved.